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Downregulation of GRK5 hampers 
the migration of breast cancer cells
Ann-Katrin Sommer1, Mathias Falcenberg2, Bojan Ljepoja1, Thomas Fröhlich3, 
Georg J. Arnold3, Ernst Wagner1 & Andreas Roidl1*
Sunitinib is a multispecific kinase inhibitor and one of its targets is the kinase GRK5, which is regulating 
a multitude of G protein-coupled receptors (GPCRs). In this study we demonstrate that a decreased 
GRK5 expression induced by knock-down experiments or sunitinib treatment hampers the migration 
of cancer cell lines. A proteomic analysis revealed many pathways related to cell migration which were 
down regulated upon the GRK5 knock-down. Furthermore, we found in MDA-MB-231 breast cancer 
cells that the inhibition of migration is mediated by the GPCR gastrin releasing peptide receptor (GRPR) 
leading to a reduced expression of migration regulating downstream targets like CDC42 and ROCK1. 
An in silico Kaplan Meier analysis revealed that GRK5 and GRPR overexpression reduces the distant 
metastasis free survival in triple-negative breast cancer (TNBC) patients. Thus, we suggest a novel 
anti-migratory effect of impaired GRK5 expression which induces a negative feedback loop on GRPR 
signalling.
G protein-coupled receptors (GPCRs) are the largest group of cell surface receptors in humans and comprise 
of more than 800 members1. They are also known as seven-transmembrane receptors and are involved in many 
physiological processes like neurotransmission, metabolism, immune response, regulation of blood pressure and 
cardiac activity2. Therefore, a tight regulation of these signalling cascades is of great importance to avoid disease 
formation. One regulatory protein class are the AGC kinases to which the G protein-coupled receptor kinase 
(GRK) family belongs. These seven serine-threonine kinases can be categorized according to their structural 
properties into three subgroups: the visual subfamily (GRK1, GRK7), the GRK2 subfamily (GRK2, GRK3) and 
the GRK4 subfamily (GRK4, GRK5, and GRK6)3,4. In general, all GRKs regulate the GPCR signalling by phos-
phorylating agonist-activated GPCRs in the third cytoplasmic loop and/or the C-terminal tail. This leads to the 
recruitment of β-arrestins and subsequently to the uncoupling of the G proteins. This process is termed GPCR 
desensitization5,6. β-arrestins are also known to function as scaffold proteins that facilitate the internalization of 
GPCRs thus resulting in the recycling or lysosomal degradation of the receptor7.
Due to the fact that the seven GRKs regulate more than 800 GPCRs it is obvious that GRKs affect the sig-
nal transduction of complex signalling cascades which comprise of more than one GPCR. Therefore, aberrant 
expression of these kinases leads to malfunction of several GPCRs and consequently to diseases like diabetes, 
hypertension, cardiac dysfunction, Alzheimer’s disease and cancer1,5. Tumorigenesis was shown to be influenced 
mainly by GRK2 and GRK58–10. These kinases often function as oncogenes in glioblastoma11, prostate9,12, pan-
creas13, non-small-cell lung14 and breast cancer15. According to the Human Protein Atlas, 50% of the analysed 
breast cancer patients possessed elevated GRK2 or GRK5 expression16,17, whereas the latter was shown to result 
in even worse prognosis concerning the 5-years survival rate. Nevertheless, the role of GRK5 in breast cancer has 
not been studied and the mechanism of action remains rather unclear. Breast cancer affects one of eight women 
during their lifetime and is estimated to be the second leading cause of cancer deaths in women in the United 
States in 201818. Therefore, it is of great importance to identify novel predictive biomarkers and druggable targets 
associated with this disease.
Therefore, the aim of this study was to elucidate the function of GRK5 in breast cancer and investigate whether 
the targeting of GRK5 could have a beneficial effect on cancer treatment. Sunitinib is the most potent, approved 
small-molecule inhibitor (SMI) targeting GRK519,20. Since 2006 sunitinib is approved by the FDA for the treat-
ment of gastrointestinal stromal tumours, which are refractory or intolerant to imatinib treatment, and for 
advanced, metastatic renal cell carcinoma (mRCC)21,22. This multispecific kinase inhibitor was shown to mainly 
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inhibit the receptor tyrosine kinases (RTKs) vascular endothelial growth factor receptor (VEGFR) and platelet 
derived growth factor receptor (PDGFR)23 thereby blocking the angiogenesis of tumours. Thus, we additionally 
investigated the effect of sunitinib on GRK5 and breast cancer cells in vitro.
Results
Analysis of different breast cancer cell lines reveals increased GRK5 expression in mesenchymal 
cells. To evaluate the expression level of GRK5 in breast cancer, a qPCR analysis was performed. The cell 
lines were grouped according to their morphology. Spindle-like cell lines were regarded as mesenchymal 
(MDA-MB-415, BT-549, MDA-MB-435s, HS-578T, MDA-MB-231) and cobblestone-like growing cells were 
considered as epithelial cells (MCF-7, BT-474, ZR-75, SKBR-3, MDA-MB-361). We observed that GRK5 is signif-
icantly higher expressed in mesenchymal-like breast cancer cells and that MDA-MB-231 cells, a metastatic, tri-
ple-negative breast cancer cell line, showed the highest GRK5 expression level of all analysed cell lines (Fig. 1A). 
A similar expression pattern was observed by western blot analysis in an additional panel of cancer cell lines 
(Supplementary Fig. S1). Therefore, MDA-MB-231 was chosen as model for further experiments.
The expression levels of the other GRK4-family members, GRK4 and GRK6, were analysed in MDA-MB-231 
cells. Here, GRK6 is as highly expressed as GRK5, whereas GRK4 shows a very low expression level (Fig. 1B).
Characterization of an inducible shGRK5 knockdown in MDA-MB-231 elucidates the impact 
of GRK5 on cell viability, apoptosis, migration and invasion in breast cancer. In order to further 
investigate the function of GRK5 in triple-negative breast cancer (TNBC), MDA-MB-231 cells stably expressing 
a doxycycline inducible shGRK5 were generated (termed MDA-MB-231 TRIPZ-shGRK5 in the following). As a 
gene coding for RFP is localized downstream of the doxycycline (DOX) inducible promotor, a fluorescence signal 
indicates shGRK5 expression upon DOX induction (Fig. 1C). Subsequently, we investigated the mRNA expres-
sion level of GRK5 in MDA-MB-231 TRIPZ-shGRK5 and MDA-MB-231 wild-type (wt) cells 72 h after inducing 
with DOX to determine the knockdown (KD) efficiency (Fig. 1C).
Moreover, possible compensatory effects of GRK4-family members were investigated in a time-dependent 
manner after DOX treatment and could be excluded as the mRNA expression levels of GRK4 and GRK6 remain 
similar after the GRK5 KD (Fig. 1D).
To elucidate the physiological impact of GRK5 KD in TNBC development and progression, cell viability and 
apoptosis induction were measured 90 h after DOX stimulation in MDA-MB-231 TRIPZ-shGRK5 cells. We 
observed that the GRK5 KD neither reduces the cell viability nor increases the apoptosis rate (Supplementary 
Fig. S2).
Proteomic analysis and boyden chamber experiments reveal impact of GRK5 on cancer cell 
migration. To investigate whether GRK5 influences breast cancer development and progression in general, a 
proteomics approach utilizing LC-MS was performed. Therefore, MDA-MB-231 TRIPZ-shGRK5 were seeded in 
quintuples, twice induced with doxycycline and harvested after 90 h (Fig. 2A). The subsequent proteomic analysis 
revealed 2220 proteins that were identified at least three times in induced and not-induced samples. The following 
gene set enrichment analysis (GSEA) utilizing Gene Ontology Biological Process (GO_BP) elucidated up and 
down regulated signalling pathways upon GRK5 KD. By clustering the resulting pathways in signalling cascades 
important for tumorigenesis it was observed that a decrease in GRK5 expression primarily leads to a down regu-
lation of cell motility pathways (Fig. 2B).
To validate the effect of GRK5 on cancer cell migration, boyden chamber experiments with and without 
matrigel coating were performed. Thereby, we showed that GRK5 KD significantly hampers both migration and 
invasion in TNBC cells (Fig. 2C,D). Additionally, a KD by a pool of GRK5 siRNAs was performed in another 
breast cancer (HS-578T) and two prostate cancer cell lines (DU-145, PC-3) (Fig. 2E) and its effect on cancer cell 
migration was confirmed (Fig. 2F).
GRK5 KD hampers chemotaxis of MDA-MB-231 cells towards bombesin. To identify the underly-
ing signalling pathways, different chemoattractants were analysed in a boyden chamber experiment with respect 
to their pro-migratory activity on MDA-MB-231 cells. Moreover, it was investigated whether this effect can be 
blocked or reduced by a siGRK5 KD. We demonstrate that only bombesin, bradykinin and insulin increased the 
migratory behaviour of MDA-MB-231 cells, which can be significantly decreased by a GRK5 KD in the case of 
bradykinin and bombesin (Fig. 3A,B). As bombesin shows the most significant change in migratory behaviour 
this ligand was analysed further.
The impact of bombesin on the migration of TNBC cells was also examined in MDA-MB-231 TRIPZ-shGRK5 
cells to exclude transfection artefacts, as transfection agents could influence cancer cell migration. Here, the 
chemotactic effect of bombesin was also reduced by shGRK5 (Fig. 3C). Furthermore, the influence of GRK5 and 
bombesin on the invasiveness of MDA-MB-231 TRIPZ-shGRK5 cells was investigated. As depicted in Fig. 3D, a 
reduction of GRK5 expression leads to a decreased invasion of TNBC cells towards a bombesin gradient.
Reduction in GRPR expression by GRK5 KD decreases chemotaxis of MDA-MB-231 towards 
bombesin. The gastrin releasing peptide receptor (GRPR) is the cellular receptor of bombesin and therefore, 
its expression levels were analysed in different breast cancer cells to confirm its impact on migration. Figure 4A 
shows that GRPR is significantly higher expressed in mesenchymal-like breast cancer cells. Subsequently, the 
influence of the GRK5 KD on the GRPR signalling pathway was investigated. Here, we observed that the auto-
crine activation loop of the GRPR signalling is hampered upon GRK5 KD since the mRNA level of GRPR as well 
as that of its natural ligand GRP was reduced (Fig. 4B). A GRPR KD on the other hand had no impact on the 
GRK5 expression (Supplementary Fig. S3). Next, the impact of GRPR on cell migration of TNBC was examined. 
We detected that GRPR KD reduces the migratory behaviour of MDA-MB-231 to a similar extent as a GRK5 KD 
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(Fig. 4C). In order to determine whether GRPR is the only GPCR that is regulated by GRK5 and thus is respon-
sible for the reduced chemotaxis towards bombesin, cells were transfected with both siGRK5 and siGRPR. As 
depicted in Fig. 4D this double-KD is not further reducing the migration of MDA-MB-231 cells indicating that 
GRPR is the main player in the chemotactic process which is regulated by GRK5.
Figure 1. Expression analysis of GRK5 and characterization of MDA-MB-231 TRIPZ-shGRK5. (A) Expression 
analysis of GRK5 in different breast cancer cell lines utilizing qPCR. The values are depicted as mean + SD 
in the left panel and as median + range in the right panel. Student’s t-test was used for statistical evaluation. 
(B) Expression analysis of GRK4 family members in MDA-MB-231 wild-type cells. (C) Characterization 
of MDA-MB-231 TRIPZ-shGRK5. GRK5 expression analysis and fluorescence microscopy pictures upon 
induction with 5 µg/ml doxycycline for 72 h. (D) Expression analysis of GRK4 family members at the indicated 
time points upon induction with 5 µg/ml doxycycline. N = 3, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. Proteomics, migration and invasion analysis of MDA-MB-231 TRIPZ-shGRK5. (A) Scheme of 
proteomics analysis. Cells were seeded in quintuples and stimulated with 5 µg/ml doxycycline or control every 
48 h for 90 h. Subsequently a proteomic analysis utilizing LC-MS was performed. (B) Overview of up and down 
regulated pathways revealed by GSEA. Gene ontology biological process was utilized as dataset. (C) Migration 
analysis of MDA-MB-231 TRIPZ-shGRK5 90 h upon stimulation with doxycycline or control using a boyden 
chamber migration assay. Representative pictures are shown. (D) Invasion analysis utilizing matrigel coated 
boyden chambers 90 h after stimulation 5 µg/ml doxycycline or control. (E) Western blot analysis of HS-578T, 
DU-145 and PC-3 72 h upon siGRK5 KD. The presented blots were cropped (F) Migration analysis of HS-578T, 
DU-145 and PC-3 90 h upon transfection with sc.ctr. or siGRK5. Relative migration or invasion is shown as 
mean + SD normalized to not induced or sc.ctr. transfected samples (N = 3). A two-tailed Student’s t-test was 
performed. *p < 0.05, **p < 0.01, ***p < 0.001.
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By comparing the measured migration data, we observed a constant reduction in the migratory behaviour of 
25–30% upon GRK5 KD, GRPR KD and the double KD of GRK5 and GRPR emphasizing the key role of GRPR 
in GRK5 mediated migration.
Figure 3. Evaluation of chemoattractants with regard to their migration stimulating capabilities in 
MDA-MB-231 cells and the blockage thereof by GRK5 KD. (A) Western blot analysis of MDA-MB-231 72 h 
upon siGRK5 KD. The presented blots were cropped. (B) Screening of different chemoattractants. The indicated 
ligands were added in the lower well at the following concentrations: Angiotensin 100 nM, Bombesin 200 nM, 
Bradykinin 5 µM, Endothelin 100 nM, Glucose 4.5 g/ml, Insulin 10 µg/ml, LPA 10 µM. Relative migration values 
are depicted as mean + SD and are normalized to untreated, sc.ctr. transfected cells (N = 3). (C) Analysis of 
migratory behaviour of MDA-MB-231 TRIPZ-shGRK5 cells 90 h upon induction with 5 µg/ml doxycycline 
or control with or without stimulation with 200 nM bombesin. Cells were stained with crystal violet and 
representative pictures are shown (N = 3). (D) Invasion analysis of MDA-MB-231 TRIPZ-shGRK5 90 h upon 
induction with 5 µg/ml doxycycline or control with or without stimulation with 200 nM bombesin. Cells 
were stained with crystal violet and representative pictures are shown. Values are depicted as mean + SD and 
are normalized to not induced, not stimulated samples (N = 3). One-way ANOVA with Dunnett’s Multiple 
Comparison Test and multiple t-tests utilizing two-stage linear step-up procedure of Benjamini, Krieger and 
Yekutieli was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. Correlation of GRK5 and GRPR and their impact on migration. (A) Expression analysis of GRPR 
in different breast cancer cell lines utilizing qPCR. The values are depicted as mean + SD in the left panel and 
as median + range in the right panel. Student’s t-test was used for statistical evaluation. (B) Expression analysis 
of GRK5, GRPR and GRP 90 h upon induction with 5 µg/ml doxycycline utilizing qPCR. Values are depicted 
as mean + SD. Two-tailed Student’s t-test was utilized for statistical evaluation. (C) Migration analysis of 
MDA-MB-231 cells 90 h upon transfection with sc.ctr. or siGRPR with and without stimulation with 200 nM 
bombesin. Representative pictures of the crystal violet staining are shown at the right panel. Relative migration 
values are depicted as mean + SD and normalized to sc.ctr. transfected, not stimulated samples. (N = 3). (D) 
Migration analysis of MDA-MB-231 cells 90 h after transfection with sc. ctr. or siGRK5 and siGRPR, with 
or without bombesin stimulation using a boyden chamber assay. Representative pictures of the crystal violet 
staining are shown. The relative migration values are normalized to sc.ctr. transfected, not stimulated samples 
and depicted as mean + SD (N = 3). For statistical evaluation one-way ANOVA with Dunnett’s Multiple 
Comparison Test was used. *p < 0.05, **p < 0.01, ***p < 0.001.
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Sunitinib treatment hampers cell migration by reducing the expression of GRK5 and 
GRpR. Sunitinib is the most potent, approved GRK5 inhibitor19,20. To evaluate the clinical relevance of our find-
ings MDA-MB-231 cells were treated with this SMI and its effect on cell viability, migration, GRK5 and GRPR 
expression as well as GRPR signalling was investigated. Figure 5A shows that 5 µM sunitinib treatment reduces the 
cell viability of TNBC cells. Therefore, only lower, non-toxic concentrations were utilized for the cell migration anal-
ysis. Here, we demonstrated that 1 µM sunitinib treatment significantly reduces the migration of breast cancer cells. 
A similar effect was detected for the GRK5 KD. The impact of sunitinib treatment on the expression of GRK4-family 
members was investigated. Sunitinib significantly reduces the expression only of GRK5 - no significant expression 
changes were observed for GRK4 and GRK6 (Fig. 5B). Additionally, sunitinib significantly decreases the expression 
of GRPR and down-stream targets like CDC42 and ROCK1 (Fig. 5C). To investigate whether the GRK5 inhibition, 
which leads to impaired GRPR signalling and eventually reduced migration, has an impact on patient survival, we 
analysed patient data in silico. The Kaplan-Meier Plotter24 revealed that GRK5 and GRPR overexpression shows a 
tendency to reduce the distant metastasis free survival (DMFS) in TNBC patients (Fig. 5D). Therefore, we hypothe-
size that sunitinib treatment of TNBC prolongs DMFS and thus could improve the patient outcome (Fig. 6).
Discussion
Previous studies have shown that GRK5 affects the migration of prostate cancer via moesin12 and of non-small 
cell lung cancer cells via vinculin14. However, the function of GRK5 in breast cancer and the involved GPCRs 
remain unclear. In this study, a breast cancer cell line screen revealed that GRK5 is mainly expressed in TNBC 
cell lines, which possess a mesenchymal like phenotype and are able to migrate. Accordingly, the GRK5 KD by 
a pool of siRNAs and the inducible shRNA in MDA-MB-231 cells reduced cell migration and invasion as well 
as the expression of proteins involved in cell migration pathways. In order to uncover the responsible GPCRs 
different ligands were used as chemoattractants. Here, bombesin stimulation, amongst others, resulted in sig-
nificantly increased cell migration which can be blocked by the GRK5 KD, mediated by both, the siRNA and 
shRNA approach. This finding led to the assumption that GRK5 interferes with the GRPR signalling pathway, as 
bombesin, an artificial ligand, binds and activates the GRPR25–27. GRPR is an important receptor in breast cancer 
and is overexpressed in up to 96% of breast cancer patients28. An elevated GRPR expression in breast cancer tissue 
worsens the prognosis16,17. Our expression analysis in different breast cancer cell lines revealed that GRPR is sig-
nificantly higher expressed in mesenchymal like breast cancer cell lines and correlates with the GRK5 expression. 
The subsequent qPCR analysis of GRPR and its natural ligand GRP upon GRK5 KD displayed decreased GRPR 
and GRP expression. Vice versa the KD of GRPR had no influence on the GRK5 expression. Thus, the GRK5 KD 
hampers the autocrine signalling mechanism by inhibiting the expression of both the endogenous ligand as well 
as that of the corresponding receptor. GRPR is the sole receptor involved in the chemotaxis of cancer cells towards 
the ligands GRP/bombesin29,30. The decrease in its expression by GRK5 KD therefore directly impacts the migra-
tion of cancer cells. It was previously shown that the increase in GRPR signalling leads to enhanced cancer cell 
migration and invasion in various cancer types31,32. However, there are many more GPCRs involved in migration 
like the bradykinin receptor33, angiotensin receptor34, endothelin receptor35 and thrombin receptor36.Our ligand 
screen however revealed, that only bradykinin and bombesin stimulated migration was hampered by the GRK5 
KD and are thus the crucial pathways influenced by GRK5. Moreover, we performed a KD with siRNAs against 
GRPR and a double KD with siRNAs against GRK5 and GRPR, and investigated the effect on migration. It was 
shown that all analysed KD experiments with siGRK5, shGRK5, siGRPR and the double KD of GRK5/GRPR, 
had the same impact on cell migration. We therefore conclude, that the GRPR signalling pathway is an important 
migratory mechanism which is regulated by GRK5. The knock-down of GRK5 activates a negative feedback loop 
by attenuating the expression of GRP and GRPR, finally leading to reduced migration in our in vitro system.
To evaluate the clinical significance of our findings, TNBC cells were treated with sunitinib, the most potent, 
FDA approved GRK5 inhibitor19,20. We observed that sunitinib hampers the migration of MDA-MB-231 cells at 
non-toxic doses. Previously, it was already shown that sunitinib hampers cell migration in different cancer sub-
types but only at toxic doses37,38. Thus, these studies hardly allow a clear discrimination between cytotoxicity and 
migration. Furthermore, we performed an expression analysis of all GRK4-family members, GRPR and GRPR 
down-stream signalling components to elucidate whether the effect of sunitinib on cancer cell migration is based 
on the GRK5-GRPR signalling cascade. As sunitinib is a multispecific kinase inhibitor this SMI inhibits besides 
GRK5 e.g. VEGFR and PDGFR19,20,38,39. Our results show, that sunitinib treatment not only inhibits GRK5 but 
also significantly reduces its expression whereas GRK4 and GRK6 expression remains stable. Additionally, we 
observed that sunitinib treatment reduced the expression of GRPR and down-stream signalling components. 
As GRPR is no reported target gene of sunitinib, it is likely that sunitinib decreases the expression of GRK5 thus 
indirectly leading to the downregulation of GRPR and its downstream targets RAC1, CDC42 and ROCK1. The 
latter three proteins belong to the Rho GTPase family and are crucial players in cell migration40,41. Previous stud-
ies have shown that increased CDC42 and ROCK1 expression directly correlates with elevated actomyosin con-
tractility, actin turnover and actin polymerization and eventually facilitate the migration of cancer cells42. Thus, 
sunitinib treatment of TNBC cells might reduce their ability to migrate by down regulating GRK5 resulting in the 
decreased expression of GRP, GRPR, CDC42 and ROCK1. Moreover, this finding might mechanistically explain 
the prolonged survival of mRCC patients upon sunitinib treatment43. Here, this therapy not only reduces the met-
astatic burden but also avoids the development of new metastases and thus leads to an improved patient outcome.
Taken together, this study shows that GRK5 KD hampers the chemotaxis of MDA-MB-231 cells towards bombe-
sin by down regulating the GRPR. Furthermore, we observed that treatment with the multispecific kinase inhibitor 
sunitinib decreases the cancer cell migration by reducing the GRK5 expression levels resulting in attenuated GRPR 
signalling, depicting a novel mechanism of action of a well-known drug. We therefore encourage further studies on 
this mechanism and speculate, that the implementation of sunitinib in TNBC treatment regimen could be a promis-
ing option to reduce the formation of metastases which is still one of the major obstacles in the treatment of TNBC.
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Figure 5. Analysis of clinical impact. (A) MDA-MB-231 cells were treated for 90 h with the indicated 
concentrations of sunitinib. Left panel: Cell viability measurement by CellTiter-Glo luminescent cell viability 
assay. Right panel: Migration analysis by boyden chamber. Values are presented as mean + SD and are 
normalized to untreated cells. For statistical evaluation one-way ANOVA with Dunnett’s Multiple Comparison 
Test was used (N = 3). (B) Gene expression analysis of GRK4-family members. Values are presented as 
mean + SD and are normalized to untreated cells. For statistical evaluation multiple t-tests utilizing two-stage 
linear step-up procedure of Benjamini, Krieger and Yekutieli, were used (N = 3). (C) Gene expression of GRPR 
and GRPR down-stream signaling components. Values are presented as mean + SD and are normalized to 
untreated cells. For statistical evaluation student’s t-test (left panel) and multiple t-tests (right panel) utilizing 
two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, were used. (D) Kaplan Meier analysis24 
of GRK5 and GRPR overexpression. The influence on distant metastasis free survival (DMFS) in breast cancer 
patients with basal like tumours is depicted. *p < 0.05, **p < 0.01, ***p < 0.001.
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Materials and Methods
Reagents. Doxycycline hyclate was purchased from Sigma-Aldrich (St. Louis, Missouri, USA) (cat.nr. 
D9891). Bombesin acetate salt hydrate (cat.nr. B4272), Bradykinin acetate salt (cat.nr. B3259), human angio-
tensin II (cat.nr. A9525), endothelin I (cat.nr. E7764), lysophosphatidic acid sodium salt (cat.nr. L7260), human 
thrombin (cat.nr. T4393), glucose (cat.nr. D7021) and human insulin (cat.nr. I3536) were purchased from Sigma-
Aldrich. Sunitinib malate was purchased from Sigma-Aldrich (cat.nr. PZ0012). Lipofectamine 3000 was pur-
chased from ThermoFisher Scientific (Waltham, Massachusetts, USA) (cat.nr. L3000008).
cDNA of different breast cancer cell lines. The cDNA of the different breast cancer cell lines was a kind 
gift of Axel Ullrich’s lab.
Cell culture. MDA-MB-231 cells were obtained from DSMZ (Braunschweig, Germany) MDA-MB-231 
TRIPZ-shGRK5 were generated in our lab and both were cultured in DMEM high glucose supplemented with 
10% fetal calf serum (FCS, Gibco) at 37 °C and 5% CO2. HS-578T, DU-145 and PC-3 were obtained from ATCC 
(Manassas, Virginia, USA) and cultured according to manufacturer’s instructions. All cells were authenticated 
according to ANSI/ATCC standard ASN-0002 and routinely tested and confirmed as mycoplasm free.
Generation of stable MDA-MB-231 TRIPZ-shGRK5. MDA-MB-231 cells were transduced with the 
doxycycline-inducible TRIPZ-shGRK5 [Clone-ID: V3THS_312367; Sequence: TCGTGAGCAGCATCTTGCA 
(Dharmacon)] construct utilizing a 2nd generation lentiviral system generated with the plasmids pCMV-dR8.2 
dvpr (Addgene plasmid # 8455) and pCMV-VSV-G (Addgene plasmid # 8454), which were a gift from Bob 
Weinberg44. After transduction, a 48 h selection with 5 µg/ml puromycin was performed.
Stimulation of the cells with doxycycline was performed in a concentration of 5 µg/ml in DMEM high glu-
cose + 10% FCS for 90 h for mRNA, protein, migration and invasion analysis. Medium was replaced with fresh, 
doxycycline containing medium every 48 h to compensate for doxycycline degradation.
siRNA transfection. For siRNA transfection 300 000 cells/well were seeded in a 6-well plate and transfected 
at the same time with 5 µl Lipofectamine 3000 and 12.5 pmol siRNA per well.
 siGRK5: SMARTpool: ON-TARGETplus Human GRK5 siRNA (L-004626-02, Dharmacon, Lafayette, 
Colorado, USA)
scramble control: ON-TARGETplus Non-targeting Pool (D-001810-10, Dharmacon)
siGRPR: Silencer Select siGRPR s6230 (4392420, Thermo Fisher)
RNA-lysis and purification. 90 h prior to RNA lysis cells were seeded at a confluence of 50% and either 
transfected with siRNA or stimulated with doxycycline. Subsequently cells were harvested using RNeasy Mini Kit 
(Qiagen, Venlo, Netherlands) following the manufacturer’s protocol.
cDNA synthesis. Upon RNA purification 1000 ng RNA were taken to synthesize cDNA according to manu-
facturer’s protocol using qScript cDNA Synthesis Kit (Quantabio, Beverly. Massachusetts, USA).
Quantitative polymerase chain reaction (qPCR). To analyse the mRNA expression a qPCR was per-
formed using the LightCycler 480 (Roche, Basel, Switzerland), the Universal Probe Library (UPL, Roche) and 
LighCycler 480 Probes Master (Roche). The examined mixture contained 10 µl Probes Master, 4.4 µl nuclease 
free water, 0.2 µl left primer (20 µM), 0.2 µl right primer (20 µM), 0.2 µl probe and 5 µl cDNA per well. The utilized 
primer probe pairs are listed in the table below.
Figure 6. Supposed mechanism. GRK5 phosphorylates the GRPR upon bombesin binding. This leads to the 
activation of GRPR down-stream signalling and subsequently to the transcription of proteins like FLNA, PLAU 
and CD47. The final consequence is the maintenance of cell polarity and tension enabling cell migration which 
could be therapeutically exploited by inhibiting this pathway with sunitinib treatment.
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For quantification the 2−ΔCt or the 2−ΔΔCt method was applied and GAPDH was used as an internal standard.
Protein lysis and western blot. Cells were lyzed at 80% confluence or 72 h after siRNA transfection with 
RIPA buffer containing 1% Triton X. 30 μg protein were separated using a SDS-PAGE and subsequently trans-
ferred to a nitrocellulose membrane. After one hour blocking with TRIS-buffered saline with Tween20 (TBST) 
containing 3% nonfat dry milk, the blots were incubated overnight at 4 °C with GRK5-antibody (Millipore, 
Burlington, Massachusetts, USA, cat.nr. 05-466) solution in TBST containing 3% nonfat dry milk, followed by 
several washing steps. Afterwards, membranes were incubated for one hour in horseradish peroxidase conju-
gated anti-mouse (goat anti-mouse-hrp, Sigma Aldrich) secondary antibody at room temperature. After addi-
tional washing steps, detection was performed using enhanced chemiluminscence (ECL, GE Healthcare, Chicago, 
Illinois, USA) on X-ray films (Amersham Hyperfilm ECL, GE Healthcare). The α-Tubulin antibody (Sigma 
Aldrich, cat.nr. T9026) was used as loading control.
Evaluation of cell viability and apoptosis induction. To determine the impact of doxycycline and the 
GRK5 KD on cell viability the CellTiter-Glo luminescent cell viability assay (Promega, Madison, Wisconsin, USA) 
was utilized. To assess the apoptosis induction upon doxycycline treatment and GRK5 KD the Caspase-Glo 3/7 
Assay (Promega) was used. 90 h prior to both measurements 3 000 cells/well of MDA-MB-231 TRIPZ-shGRK5 
cells were seeded in 96-well plates and treated with the indicated concentrations of doxycycline (N = 3).
Proteomics sample preparation. For proteomics analysis 300 000 cells/well were seeded (N = 5) in a 6-well 
plate and stimulated every 48 h with 5 µg/ml doxycycline for 90 h. Subsequently, cells were washed three times with 
cold PBS and lysed with a buffer containing 8 M urea and 400 mM ammonium bicarbonate. Ultrasound was used to 
support cell lysis and finally the protein samples were purified using QIA-shredder devices (Qiagen). For reduction, 
30 µg of total protein was incubated for 30 min at a final concentration of 5 mM dithioerythritol (DTE). Cleaved 
bisulfide bonds were blocked using iodoacetamide (final concentration 15 mM) for 30 min in the dark. After dilu-
tion with water to a concentration of 1 M urea, proteins were first digested for 4 h with 300 ng LysC (FUJIFILM 
Wako Pure Chemicals, Osaka, Japan) and subsequently digested over night with 600 ng porcine trypsin (Promega, 
Madison, WI, USA) at 37 °C. Peptides were separated and identified on an Ultimate 3000 (Thermo Scientific, 
Waltham, MA, USA) nano-chromatography system coupled to a QExavtive HF-X instrument (Thermo Scientific). 
2.5 µg of peptides were dissolved in 15 µl solvent A (0.1% formic acid in water) and transferred to a capillary trap 
column (PepMap 100 C18, 100 µm × 2 cm, 5 µM particles, Thermo Scientific). Separation was performed at 250 
nL/min (Column: PepMap RSLC C18, 75 µm × 50 cm, 2 µm particles, Thermo Scientific) with a 160 min gradient 
from 5% solvent A to 25% solvent B (0.1% formic acid in acetonitrile) and a subsequent 10 min gradient from 25% 
to 40% solvent B. MS spectra were acquired using a top 15 data dependent CID method. Precursor spectra were 
acquired at a resolution 60,000 (mass-range: 350–1600) and MS/MS spectra at a resolution of 15,000.
Migration and invasion analysis. For migration and invasion analysis cells were transfected with siRNA or 
stimulated with 5 µg/ml doxycycline 72 h prior to the experiment. Subsequently, 750 µl DMEM high glucose supple-
mented with 0.5% FCS and the indicated ligand was added to the lower well of the boyden chamber system Corning 
BioCoat Matrigel Invasion Chamber (Corning, Corning, New York, USA) in the case of invasion analysis and Falcon 
Cell Culture Inserts ([8 µm pores] Coring) in the case of migration analysis. The inserts (N = 3) were filled with 
500 µl of a cell suspension containing 50 000 cells in DMEM high glucose supplemented with 0.5% FCS. 18 h later 
the cell suspension was removed and the inserts were put into 500 µl crystal violet solution containing 20% methanol 
for at least 10 min. Finally, the inserts were washed three times with demineralized water and kept overnight at room 
temperature. To determine the amount of migrated/invaded cells five microscopic pictures (magnification 10x) of 
each insert were made (top, bottom, left, right, center) and afterwards analysed using the ImageJ software.
Sunitinib treatment. For cell viability measurement 3 000 MDA-MB-231 cells/well were seeded in trip-
licates in a 96-well plate and treated with the indicated concentrations for 90 h. Afterwards the CellTiter-Glo 
luminescent cell viability assay (Promega) was utilized to measure cytotoxicity. To analyse the impact of sunitinib 
on migration 300 000 cells/well were seeded in a 6-well plate and pre-treated with sunitinib at the indicated con-
centrations for 72 h. Subsequently, sunitinib was added to the starvation medium (DMEM + 0.5% FCS) for the 
following boyden chamber experiment. Here, 50 000 cells/well were seeded in triplicates to the insert. For gene 
expression analysis 300 000 MDA-MB-231 cells/well were seeded in 6-well plates and treated with 1 µM sunitinib 
for 90 h.
Bioinformatics. Statistical significance was calculated utilizing a two-tailed Student’s t-test for the compar-
ison of two samples and one-way ANOVA with Dunnett’s Multiple Comparison Test or multiple t-tests utilizing 
left primer right primer probe
GRK5 aagtccatctgcaagatgctg ggggtgtctcttgacctctg # 26
GRPR cccgtggaagggaatataca gcggtacaggtagatgacatga # 36
GRP cagccacctcaacccaag tggagcagagagtctaccaactt # 61
ROCK1 gatcccaaatcggaagtgaa caaatcatataccaaagcatccaa # 42
CDC42 tggagtgttctgcacttacaca ggctcttcttcggttctgg # 37
RAC1 ctgatgcaggccatcaagt caggaaatgcattggttgtg # 77
GAPDH tccactggcgtcttcacc ggcagagatgatgaccctttt # 45
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two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli,for the comparison of several samples 
with the control. *p < 0.05, **p < 0.01, ***p < 0.001.
To process the mass spectrometry (MS) data MaxQuant 1.5.1.0 was applied45 and the Perseus module was 
used46. For label free quantification (LFQ) values of the identified proteins were taken and proteins that were only 
identified by site or potential contaminants were excluded.
The doxycycline induced (+DOX) and the not induced (−DOX) samples were grouped and at least three 
valid values in each group were necessary to enter further analysis. The missing values were replaced from normal 
distribution using the imputation feature of Perseus (width, 0.3; down-shift, 1.8). Subsequently, a gene set enrich-
ment analysis (GSEA) was performed using gsea2-2.2.3 from the Broad Institute (Cambridge, MA, USA)47,48. 
As underlying gene set database the gene ontology biological process (GO_BP) was used49. The resulting, dif-
ferentially expressed pathways were grouped in the following categories: metabolism, signalling, migration, cell 
differentiation, transport, cell development, immune system, gene expression and cell cycle to allow a comparison 
of up and down regulated signalling cascades.
In order to elucidate the clinical significance of GRK5 and GRPR in breast cancer patients the 
Kaplan-Meier-Plotter was utilized24 (released 2018/05/01). This web service allows the evaluation of more than 
20,000 genes in about 1,800 breast cancer patients. MDA-MB-231 cells represent an example for a triple-negative 
breast cancer with a basal subtype according to its gene expression profile. Thus, patients with basal like tumours 
were analysed and the filters were set accordingly. Distant metastasis free survival (DMFS) was chosen as end-
point as cancer cell migration and invasion were of special interest in this study.
Data availability
Data for GSEA are available at https://doi.org/10.6084/m9.figshare.7415633.
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